Cencora, Inc. business relationships
Companies named in Cencora, Inc.’s 10-K filed 2025-11-25, and public companies whose annual reports name Cencora, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 90 / 100 Top 1% in its category
- Agent readiness
- 10 / 100
- AI adoption
- 0 / 100
Named in Cencora, Inc.’s annual report 5
“As of September 30, 2025, our two largest trade receivable balances due from customers (Walgreens and Boots together and Evernorth Health Services) represented approximately 38% and 5% of our accounts receivable, net.” SEC filing
“From an operational perspective, we are the primary distributor of pharmaceutical products for Walgreens in the U.S. and Boots in the U.K. If our operations are seriously disrupted for any reason deemed within our control, we may have an obligation to pay or credit Walgreens or Boots for any resulti...” SEC filing
“(iv) changes in the economic terms under which we distribute pharmaceuticals to Walgreens pharmacies in the U.S. or to pharmacies operated by Boots. in the U.K., including changes necessitated by changing market conditions or other unforeseen developments that may arise during the term of either dis...” SEC filing
“In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue.” SEC filing
“The Company and TPG Inc. ("TPG") are party to a series of put and call options governing the remaining interests in the joint venture, including TPG's interest.” SEC filing
Companies whose annual reports name Cencora, Inc. 32
“Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2025, 2024 and 2023.” SEC filing
“(1) As of December 31, 2025, the majority of our Accounts receivable balance arises from product sales in the U.S. and Europe and approximately 60 % relates to three wholesalers-Cardinal Health, Cencora and McKesson-and their specialty distributor affiliates.” SEC filing
“The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22 %, 21 % and 13 %, respectively, of total accounts receivable at December 31, 2025.” SEC filing
“The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 579,065 million, JPY 578,767 million and JPY 436,951 million, respectively, for the year ended March 31, 2024.” SEC filing
“In the fiscal year ended March 31, 2026, there were two wholesale distributors, McKesson Group and Cencora Group, that each individually accounted for over ten percent of Takeda's total revenue.” SEC filing
“Our largest customer, an affiliate of Cencora, Inc., is a third-party veterinary distributor and represented approximately 12% of our total revenue in 2025.” SEC filing
“For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.” SEC filing
“For example, large wholesalers and retailer customers have formed alliances, such as Walgreens and Cencora, Inc., Rite Aid and McKesson Drug Company, and CVS Caremark and Cardinal Health.” SEC filing
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.-McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.-each accounted for a significant percentage of our consolidated revenue.” SEC filing
“The Company's customers with the largest accounts receivable balances are McKesson Corporation and Cencora, Inc., which represented approximately 14 % and 7 %, respectively, of total gross accounts receivable at December 31, 2025.” SEC filing
“In addition, we rely heavily on the three largest pharmaceutical wholesalers in the U.S. market-Cardinal Health Inc., Cencora, and McKesson Corp-in the distribution of ARISTADA and ARISTADA INITIO, LYBALVI and VIVITROL.” SEC filing
“We conduct business with the three major wholesalers in the U.S.: Cencora, Inc., Cardinal Health, and McKesson.” SEC filing
“The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, Cencora Inc., Cardinal Health, Inc. and McKesson Specialty.” SEC filing
“We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.” SEC filing
“The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambu...” SEC filing
“...rough numerous additional channels, including on our own website to both veterinarians and pet owners, through traditional veterinary distributors such as MWI Animal Health (Division of Cencora), Covetrus, Patterson Veterinary, and others, and through online retail channels such as Amazon and Chewy.” SEC filing
“During the year ended December 31, 2025, approximately 99% of LOQTORZI revenues were from three large wholesale distributors: McKesson Corporation , Cencora, Inc., and Cardinal Health, Inc.” SEC filing
“Zepzelca, Rylaze, Ziihera and Vyxeos are sold to customers through subsidiary specialty distributors of McKesson, Cencora, and Cardinal.” SEC filing
“Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 15% of our total product revenue in 2025 and collectively accounted for more than 76% of our total product revenue in 2025.” SEC filing
“In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States.” SEC filing
“As of December 31, 2024, three customers, BioCare, Healix Infusion Therapy, LLC ("Healix") and Cencora, Inc. (f/k/a AmerisourceBergen Corporation), represented an aggregate of approximately 91% of our consolidated accounts receivable.” SEC filing
“...he year ended December 31, 2025, sales to the Company ' s three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.5 %, 17.5 % and 10.1 % of product revenue, respectively, and collectively, represented approximately 37....” SEC filing
“...eements with WBA and/or certain of its affiliates under which the Company purchases significant volume of inventory, including a Joinder Agreement to the Pharmaceutical Purchase and Distribution Agreement (the "WBAD Membership Agreement") between WBA and AmeriSourceBergen Drug Corporation ("ABDC" ).” SEC filing
“In the event that any of our license agreements or our strategic relationship with Cencora terminates, we may need to find another partner in those markets to commercialize and in certain instances, manufacture any product candidates.” SEC filing
“We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation ("McKesson"), Cardinal Health 110, LLC ("Cardinal Health 110") and AmerisourceBergen Corporation ("AmerisourceBergen").” SEC filing
“In addition, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson” SEC filing
“For example, for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.” SEC filing
“For the fiscal year ended September 30, 2025, McKesson Corporation, Cardinal Health and Cencora, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.” SEC filing
“four pharmaceutical product wholesaler distributors: McKesson Corporation, Cencora Inc., Western Wellness and Cardinal Health, Inc. These” SEC filing
“Health's distribution agreement with AmerisourceBergen is subject to early termination in certain circumstances and, upon the expiration” SEC filing
“LYMPHIR, we have entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.” SEC filing
“We distribute Unituxin in the United States through an exclusive distribution agreement with Cencora Global Procurement Ltd ( Cencora ).” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.